Louisiana State University Health
Shreveport, Louisiana, 71103, United States
NCT Number: NCT02897232
This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify barriers which prevent these groups from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection.
The research is focused on these questions:
Do community members understand the ease of transmission of the HPV virus in males 9-26? Do community members, physicians, residents and medical students have knowledge of the associated diseases that may occur with the HPV virus infection in males age 9-26? Do community members, physicians, residents and medical students know the ages in which males should receive the HPV vaccine three-shot series? What barriers prevent community members and physicians, residents and medical students from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection?
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Shreveport, Louisiana, 71103, United States
This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify barriers which prevent these groups from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection.
The research is focused on these questions:
Do community members understand the ease of transmission of the HPV virus in males 9-26? Do community members, physicians, residents and medical students have knowledge of the associated diseases that may occur with the HPV virus infection in males age 9-26? Do community members, physicians, residents and medical students know the ages in which males should receive the HPV vaccine three-shot series? What barriers prevent community members and physicians, residents and medical students from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection?
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Community Participants
Inclusion
All visitors to the Pediatric or Internal Medicine University Health Shreveport Clinics willing to complete a survey
Community Study Exclusion
Those do not wish to participate in the study
Those who English is not their first language
Clinical Faculty, Resident, and Medical Student Study
Inclusion
All Louisiana State University Shreveport Health Clinical Faculty, Resident, and Medical Student Inclusion willing to to complete the online survey.
Clinical Faculty, Resident, and Medical Student Study
Exclusion
Any LSU Health Shreveport Clinical Faculty, Resident, and Medical Student which declines to take the survey or do not attempt to complete it.
Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
Time frame: 60 days
What are the barriers which prevent community members and physicians, residents and medical students from ensuring that males age 9-26 are vaccinated with the HPV three-shot vaccination.
Time frame: 60 days
Do community members and physicians understand the ease of HPV transmission?
Time frame: 60 days
Do community member and physicians know the associated HPV diseases?
Time frame: 60 days
Do community member and physicians know the age in which males should be vaccinated against HPV?
Louisiana State University Health Sciences Center Shreveport
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04072913
Cervix Cancer, Communicable Diseases
Bordeaux, France
View Trial DetailsNCT03903562
Communicable Diseases, DNA Virus Infections
Quzhou, Zhejiang, China
View Trial DetailsNCT06919627
Cervical Cancers, Communicable Diseases
Brest, Brittany Region, France
View Trial DetailsNCT02858310
Carcinoma, Carcinoma in Situ
Bethesda, Maryland, United States
View Trial Details